BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date Announced SOLARA-2, the single-arm pivotal Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027 Collaboration with Foundation Medicine to develop a companion diagnostic assay for the EGFR C797S resistance mutation $224.9 million in cash and cash equivalents as of September 30, 2026 SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stag